07.06.2024 - Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 30,778 shares of Evolus and an .
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of.
Evolus (NASDAQ:EOLS – Get Free Report) and Clever Leaves (NASDAQ:CLVR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Risk and Volatility Evolus has a beta of […]
HC Wainwright reissued their buy rating on shares of Evolus (NASDAQ:EOLS – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $27.00 price objective on the stock. EOLS has been the subject of a number of other research reports. Barclays upgraded Evolus from an equal weight rating to an […]
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.